TNSN04081A1 - Methodes pour le traitement de maladies neovasculaires oculaires - Google Patents

Methodes pour le traitement de maladies neovasculaires oculaires

Info

Publication number
TNSN04081A1
TNSN04081A1 TNP2004000081A TNSN04081A TNSN04081A1 TN SN04081 A1 TNSN04081 A1 TN SN04081A1 TN P2004000081 A TNP2004000081 A TN P2004000081A TN SN04081 A TNSN04081 A TN SN04081A TN SN04081 A1 TNSN04081 A1 TN SN04081A1
Authority
TN
Tunisia
Prior art keywords
treatment
methods
ocular neovascular
neovascular diseases
therapy
Prior art date
Application number
TNP2004000081A
Other languages
English (en)
Inventor
David R Guyer
Original Assignee
Eyetech Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eyetech Pharmaceuticals filed Critical Eyetech Pharmaceuticals
Publication of TNSN04081A1 publication Critical patent/TNSN04081A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/409—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. porphine derivatives, bilirubin, biliverdine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Pathology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

IL EST DECRIT DANS LE PRESENT MEMOIRE DES METHODES POUR LE TRAITEMENT D'UNE MALADIE NEOVASCULAIRE OCULAIRE EN UTILISANT UNE THERAPIE ANTI-VEGF EN ASSOCIATION AVEC UNE SECONDE THERAPIE QUI INHIBE LE DEVELOPPEMENT D'UNE NEOVASCULARISATION OCULAIRE OU QUI DETRUIT DES VAISSEAUX SANGUINS ANORMAUX DANS L'OEIL; TELLE QU'UNE THERAPIE PHOTODYNAMIQUE.
TNP2004000081A 2001-11-09 2004-05-07 Methodes pour le traitement de maladies neovasculaires oculaires TNSN04081A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33230401P 2001-11-09 2001-11-09
PCT/US2002/035986 WO2003039404A2 (fr) 2001-11-09 2002-11-08 Procedes destines a traiter des neoformations de vaisseaux sanguins oculaires

Publications (1)

Publication Number Publication Date
TNSN04081A1 true TNSN04081A1 (fr) 2006-06-01

Family

ID=23297643

Family Applications (1)

Application Number Title Priority Date Filing Date
TNP2004000081A TNSN04081A1 (fr) 2001-11-09 2004-05-07 Methodes pour le traitement de maladies neovasculaires oculaires

Country Status (26)

Country Link
US (3) US20030171320A1 (fr)
EP (1) EP1441743A4 (fr)
JP (1) JP2005511576A (fr)
KR (1) KR20050044372A (fr)
CN (1) CN1582156A (fr)
AP (1) AP1750A (fr)
AR (1) AR037307A1 (fr)
BR (1) BR0213975A (fr)
CA (1) CA2464007A1 (fr)
CR (1) CR7330A (fr)
EA (1) EA006746B1 (fr)
EC (1) ECSP045098A (fr)
GE (1) GEP20063755B (fr)
HR (1) HRP20040406A2 (fr)
IL (1) IL161327A0 (fr)
IS (1) IS7215A (fr)
MA (1) MA27145A1 (fr)
MX (1) MXPA04004363A (fr)
NO (1) NO20041882L (fr)
OA (1) OA12720A (fr)
PL (1) PL371929A1 (fr)
RS (1) RS35404A (fr)
TN (1) TNSN04081A1 (fr)
TW (1) TWI260327B (fr)
WO (1) WO2003039404A2 (fr)
ZA (1) ZA200402753B (fr)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001234979B2 (en) * 2000-02-10 2006-07-27 Massachusetts Eye And Ear Infirmary Methods and compositions for treating conditions of the eye
US6942655B2 (en) * 2001-11-13 2005-09-13 Minu, Llc Method to treat age-related macular degeneration
US6936043B2 (en) * 2001-11-13 2005-08-30 Minu, Llc Method to treat age-related macular degeneration
EP1605847B1 (fr) * 2003-03-07 2009-09-16 Board Of Regents, The University Of Texas System Therapie photodynamique ciblee sur les anticorps
CL2004001996A1 (es) * 2003-08-08 2005-05-06 Eyetech Pharmaceuticals Inc Aptameros anti-vegf (factor de crecimiento endotelial vascular) con bloqueo nucleotidico 5'-5' o 3'-3' invertido, composicion que lo contiene, util para trastornos de neovascularizacion.
US7759472B2 (en) 2003-08-27 2010-07-20 Ophthotech Corporation Combination therapy for the treatment of ocular neovascular disorders
US7575321B2 (en) * 2003-10-30 2009-08-18 Welch Allyn, Inc. Apparatus and method of diagnosis of optically identifiable ophthalmic conditions
CN105820160B (zh) 2003-11-05 2019-02-12 萨可德生物科学公司 细胞粘着调节剂
US20070224278A1 (en) 2003-11-12 2007-09-27 Lyons Robert T Low immunogenicity corticosteroid compositions
US20050101582A1 (en) 2003-11-12 2005-05-12 Allergan, Inc. Compositions and methods for treating a posterior segment of an eye
AU2005209201B2 (en) 2004-01-20 2010-06-03 Allergan, Inc. Compositions for localized therapy of the eye, comprising preferably triamcinolone acetonide and hyaluronic acid
WO2005084412A2 (fr) * 2004-03-05 2005-09-15 Archemix Corp. Modulation controlee de la pharmacocinetique et la repartition biologique de la therapeutique a base d'aptameres
US20050244469A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Extended therapeutic effect ocular implant treatments
US8119154B2 (en) 2004-04-30 2012-02-21 Allergan, Inc. Sustained release intraocular implants and related methods
US20060182783A1 (en) * 2004-04-30 2006-08-17 Allergan, Inc. Sustained release intraocular drug delivery systems
US8147865B2 (en) 2004-04-30 2012-04-03 Allergan, Inc. Steroid-containing sustained release intraocular implants and related methods
US7528106B2 (en) * 2004-06-04 2009-05-05 The Scripps Research Institute Compositions and methods for treatment of neovascular diseases
EP1776474A2 (fr) * 2004-07-23 2007-04-25 (Osi) Eyetech, Inc. Detection d'oligonuleotides par hybridation double
JP2006056807A (ja) * 2004-08-18 2006-03-02 Konica Minolta Medical & Graphic Inc 光線力学療法製剤
AU2012200865A1 (en) * 2004-10-21 2012-03-29 Genentech, Inc. Method for treating intraocular neovascular diseases
DK1802334T3 (da) * 2004-10-21 2012-10-15 Genentech Inc Fremgangsmåde til behandling af intraokulære, neovaskulære sygdomme
WO2006047716A2 (fr) * 2004-10-26 2006-05-04 Bioresponse Llc Utilisation d'indoles lies au diindolylmethane et d'inhibiteurs du recepteur de facteur de croissance pour le traitement d'une maladie associee au cytomegalovirus humain
AU2005309854A1 (en) * 2004-11-24 2006-06-01 Therakine Ltd. An implant for intraocular drug delivery
US20060134174A1 (en) * 2004-12-22 2006-06-22 Bausch & Lomb Incorporated Pharmaceutical delivery system and method of use
US20060134175A1 (en) * 2004-12-22 2006-06-22 Stephen Bartels Drug eluting pharmaceutical delivery system for treatment of ocular disease and method of use
US20060134176A1 (en) * 2004-12-22 2006-06-22 Bausch & Lomb Incorporated Pharmaceutical delivery system and method of use
EP1848431B1 (fr) 2005-02-09 2016-02-03 Santen Pharmaceutical Co., Ltd. Formulations liquides pour le traitement de maladies ou affections
US8663639B2 (en) 2005-02-09 2014-03-04 Santen Pharmaceutical Co., Ltd. Formulations for treating ocular diseases and conditions
KR20070121754A (ko) * 2005-03-21 2007-12-27 마커사이트, 인코포레이티드 질환 또는 상태의 치료를 위한 약물 송달 시스템
US20060293270A1 (en) * 2005-06-22 2006-12-28 Adamis Anthony P Methods and compositions for treating ocular disorders
WO2007037188A1 (fr) * 2005-09-27 2007-04-05 Sapporo Medical University Produit pharmaceutique destiné au traitement et à la prévention d’une pathologie ophtalmique induite par une augmentation de la vasoperméabilité
US8168584B2 (en) 2005-10-08 2012-05-01 Potentia Pharmaceuticals, Inc. Methods of treating age-related macular degeneration by compstatin and analogs thereof
US20090098139A1 (en) * 2006-01-30 2009-04-16 Barrett Katz Combination therapy for the treatment of neovascular disorders
WO2007092620A2 (fr) 2006-02-09 2007-08-16 Macusight, Inc. Formulations stables et leurs procedes de preparation et d'utilisation
US20070248646A1 (en) * 2006-02-16 2007-10-25 Ali Hafezi-Moghadam Use of azurocidin inhibitors in prevention and treatment of ocular vascular leakage
US20070218007A1 (en) * 2006-03-17 2007-09-20 Allergan, Inc. Ophthalmic visualization compositions and methods of using same
ES2563288T3 (es) 2006-03-23 2016-03-14 Santen Pharmaceutical Co., Ltd Rapamicina en dosis bajas para el tratamiento de enfermedades relacionadas con la permeabilidad vascular
HUE053612T2 (hu) * 2006-06-16 2021-07-28 Regeneron Pharma Intravitreális bevitelre alkalmas VEGF-antagonista készítmények
US8668676B2 (en) * 2006-06-19 2014-03-11 Allergan, Inc. Apparatus and methods for implanting particulate ocular implants
US9039761B2 (en) 2006-08-04 2015-05-26 Allergan, Inc. Ocular implant delivery assemblies with distal caps
WO2008103320A1 (fr) * 2007-02-16 2008-08-28 Novacea, Inc. Méthodes de traitement de troubles ophtalmiques utilisant des anthraquinones
JP2008308489A (ja) * 2007-05-11 2008-12-25 Santen Pharmaceut Co Ltd ロピニロール又はその塩を有効成分として含有する後眼部疾患の予防又は治療剤
US9125807B2 (en) 2007-07-09 2015-09-08 Incept Llc Adhesive hydrogels for ophthalmic drug delivery
ES2830024T3 (es) * 2007-10-19 2021-06-02 Novartis Ag Composiciones y métodos para el tratamiento del edema macular
WO2010045506A2 (fr) * 2008-10-16 2010-04-22 Kathleen Cogan Farinas Système d'administration prolongée de médicament
US8530189B2 (en) * 2008-10-16 2013-09-10 Kathleen Cogan Farinas Sustained drug delivery system
JP5988584B2 (ja) 2008-12-16 2016-09-07 キュー エル ティー インク．ＱＬＴ Ｉｎｃ． 眼の状態に関する光線力学的療法
US8545554B2 (en) * 2009-01-16 2013-10-01 Allergan, Inc. Intraocular injector
EP2393513B1 (fr) 2009-02-06 2016-10-19 The General Hospital Corporation Procédés de traitement de lésions vasculaires
WO2011009020A2 (fr) 2009-07-16 2011-01-20 Mallinckrodt Inc. Composés et compositions pour une utilisation en photothérapie et dans le traitement d'une maladie néovasculaire oculaire et de cancers
ES2468827T3 (es) * 2010-01-14 2014-06-17 Sanwa Kagaku Kenkyusho Co., Ltd Producto farmacéutico para prevenir o tratar trastornos acompañados de angiog�nesis ocular y/o permeabilidad vascular ocular elevada
US20130225603A1 (en) * 2010-09-27 2013-08-29 Serrata Llc Mdm2 inhibitors for treatment of ocular conditions
KR20180023015A (ko) 2011-01-13 2018-03-06 리제너론 파아마슈티컬스, 인크. 혈관신생 눈 장애를 치료하기 위한 vegf 길항제의 용도
CN103391782A (zh) 2011-02-02 2013-11-13 公立大学法人名古屋市立大学 用于预防或治疗伴有眼内血管新生及/或眼内血管渗透性过高的疾病的药物
KR101303920B1 (ko) * 2011-04-26 2013-09-05 서울대학교산학협력단 프로토포르피린 ＩＸ 구조를 갖는 화합물을 포함하는, 저산소상태 유도성인자1α 또는 혈관내피세포성장인자 과다 발현으로 기인하는 질병의 예방 및 치료에 유용한 조성물
TW201406707A (zh) 2012-05-04 2014-02-16 Acucela Inc 用以治療糖尿病性視網膜病變及其他眼部疾病之方法
AU2013100070B4 (en) * 2012-07-03 2013-04-04 Novartis Ag Use of device
CN103721257B (zh) * 2012-10-16 2016-12-21 无锡兆真辐射技术有限公司 光敏素催化分解过氧化氢系列药物
RS62243B9 (sr) 2012-11-15 2022-11-30 Apellis Pharmaceuticals Inc Analozi kompstatina sa produženim trajanjem dejstva i njihove kompozicije i postupci
WO2014152391A1 (fr) 2013-03-15 2014-09-25 Apellis Pharmaceuticals, Inc. Analogues de compstatine pénétrant dans les cellules et leurs utilisations
RU2527360C1 (ru) * 2013-04-23 2014-08-27 Государственное бюджетное образовательное учреждение высшего профессионального образования "Дагестанская государственная медицинская академия" Министерства здравоохранения Российской Федерации Способ комбинированного лечения ретиноваскулярного макулярного отека
BR112016000546A2 (pt) 2013-07-12 2017-11-21 Ophthotech Corp métodos para tratar ou prevenir condições oftalmológicas
WO2015099838A2 (fr) 2013-12-24 2015-07-02 Novelmed Therapeutics, Inc. Compositions et procédés de traitement de troubles oculaires
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
EP3359555B1 (fr) 2015-10-07 2023-12-20 Apellis Pharmaceuticals, Inc. Régimes posologiques
RS64725B1 (sr) 2015-12-03 2023-11-30 Regeneron Pharma Postupci dovođenja u vezu genskih varijanti sa kliničkim ishodom kod pacijenata koji pate od starosne makularne degeneracije lečenih anti- vegf-om
AU2016381964B2 (en) 2015-12-30 2024-02-15 Kodiak Sciences Inc. Antibodies and conjugates thereof
CN116059313A (zh) 2017-04-07 2023-05-05 阿佩利斯制药有限公司 给药方案以及相关组合物和方法
DE102017008721A1 (de) 2017-09-16 2019-03-21 protectismundi GmbH Verfahren und Vorrichtung zur Hochhausbrandbekämfpung
WO2019210097A1 (fr) * 2018-04-25 2019-10-31 Vitrisa Therapeutics, Inc. Aptamères ayant une stabilité, une puissance ou une demi-vie pour une sécurité et une efficacité améliorées
US11519020B2 (en) 2018-05-25 2022-12-06 Regeneron Pharmaceuticals, Inc. Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-VEGF
EP4041312A4 (fr) 2019-10-10 2023-12-20 Kodiak Sciences Inc. Procédés de traitement d'un trouble oculaire
CN113101530B (zh) * 2021-04-14 2022-09-30 中国人民解放军陆军特色医学中心 一种通过无线充电激活玻璃体腔植入性发光二极管的***
CN118108804B (zh) * 2024-04-26 2024-06-25 山东大学 一种缺氧敏感功能化修饰的抗血管生成多肽、纳米胶束材料及其制备方法与应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5770592A (en) * 1991-11-22 1998-06-23 Alcon Laboratories, Inc. Prevention and treatment of ocular neovascularization using angiostatic steroids
US5342348A (en) * 1992-12-04 1994-08-30 Kaplan Aaron V Method and device for treating and enlarging body lumens
US5731294A (en) * 1993-07-27 1998-03-24 Hybridon, Inc. Inhibition of neovasularization using VEGF-specific oligonucleotides
CA2536069C (fr) * 1994-03-14 2008-06-03 Massachusetts Eye And Ear Infirmary Utilisation de prophyrines vertes pour le diagnostic et la therapie oculaire
US5798349A (en) * 1994-03-14 1998-08-25 The General Hospital Corporation Use of green porphyrins to treat neovasculature in the eye
JP3845469B2 (ja) * 1996-02-21 2006-11-15 明治製菓株式会社 眼底の新生血管の閉塞に用いる投与剤
US5756541A (en) * 1996-03-11 1998-05-26 Qlt Phototherapeutics Inc Vision through photodynamic therapy of the eye
DK0957929T3 (da) * 1996-10-25 2006-07-03 Gilead Sciences Inc Vaskulær endotelial vækstfaktor (VEGF) nukleinsyreligandkomplekser
US6123923A (en) * 1997-12-18 2000-09-26 Imarx Pharmaceutical Corp. Optoacoustic contrast agents and methods for their use
US6117862A (en) * 1998-10-09 2000-09-12 Qlt, Inc. Model and method for angiogenesis inhibition
JP2003519670A (ja) * 2000-01-12 2003-06-24 ライト サイエンシーズ コーポレイション 眼疾患の新規処置
AU2001234979B2 (en) * 2000-02-10 2006-07-27 Massachusetts Eye And Ear Infirmary Methods and compositions for treating conditions of the eye
EP1938799B1 (fr) * 2000-03-10 2013-05-08 Insite Vision Incorporated Compositions pour le traitement et la prévention de troubles ophtalmiques du segment postérieur et leur utilisation
IL151833A0 (en) * 2000-03-24 2003-04-10 Novartis Ag Improved treatment of neovascularization
US6936043B2 (en) * 2001-11-13 2005-08-30 Minu, Llc Method to treat age-related macular degeneration
AU2003301267A1 (en) * 2002-10-18 2004-05-04 The Regents Of The University Of California Photodynamic therapy for ocular neovascularization

Also Published As

Publication number Publication date
WO2003039404A2 (fr) 2003-05-15
CR7330A (es) 2005-06-15
OA12720A (en) 2006-06-27
ZA200402753B (en) 2005-01-05
MXPA04004363A (es) 2005-05-16
US20040167091A1 (en) 2004-08-26
EA006746B1 (ru) 2006-04-28
BR0213975A (pt) 2005-05-10
IS7215A (is) 2004-04-07
HRP20040406A2 (en) 2005-02-28
AP2004003026A0 (en) 2004-06-30
RS35404A (en) 2006-10-27
EA200400518A1 (ru) 2004-12-30
MA27145A1 (fr) 2005-01-03
EP1441743A2 (fr) 2004-08-04
JP2005511576A (ja) 2005-04-28
IL161327A0 (en) 2004-09-27
NO20041882L (no) 2004-05-07
PL371929A1 (en) 2005-07-11
CN1582156A (zh) 2005-02-16
AP1750A (en) 2007-06-23
CA2464007A1 (fr) 2003-05-15
TW200302226A (en) 2003-08-01
KR20050044372A (ko) 2005-05-12
ECSP045098A (es) 2004-07-23
EP1441743A4 (fr) 2009-02-25
US20070027101A1 (en) 2007-02-01
AR037307A1 (es) 2004-11-03
TWI260327B (en) 2006-08-21
WO2003039404A3 (fr) 2004-02-12
GEP20063755B (en) 2006-02-27
US20030171320A1 (en) 2003-09-11

Similar Documents

Publication Publication Date Title
TNSN04081A1 (fr) Methodes pour le traitement de maladies neovasculaires oculaires
MA27854A1 (fr) Traitement au moyen d'anticorps anti-vegf
RU2445096C2 (ru) Способы лечения глазного ангиогенеза, ретинального отека, ретинальной ишемии и диабетической ретинопатии с использованием избирательных ингибиторов rtk
FR13C0060I2 (fr) Omega-carboxyaryldiphenyluree fluoro-subtituee pour le traitement et la prevention de maladies et d'etats pathologiques
EA200501560A1 (ru) Предотвращение и терапия амилоидогенной болезни
TNSN07063A1 (fr) Utilisations therapeutiques d'inhibiteurs de rtp801
MA30085B1 (fr) Traitement du diabete de type 2 avec une association d'un inhibiteur de dpiv et de metformine ou d'une thiazolidinedione
AU4239196A (en) Methods for the prevention or treatment of vascular hemorrhaging and alzheimer's disease
JP2007534657A5 (fr)
MA30962B1 (fr) Anticorps antifacteurs d'humanisés et leurs utilisations.
ATE324119T1 (de) Verwendung von saccharid-konjugaten
MA30868B1 (fr) Derives de 2-aminocarbonyl-pyridine
HUP0400548A2 (hu) Belső szemnyomást csökkentő hatóanyag-kombinációk alkalmazása glaukoma kezelésére szolgáló gyógyszerkészítmények előállítására
MA30903B1 (fr) Derives de 2 - phenyl-6-minocarbonyl-pyrimidine
DE60234619D1 (de) Gene und proteine für verhinderung, vorhersage, prognose und therapie der herzgefäss-krankheit
MA30665B1 (fr) Traitement de maladies rhumatoïdes avec des glucocorticoïdes a liberation retardee.
MA33579B1 (fr) Thérapie anti-angiogenèse pour le traitement d'un cancer du sein précédemment traité
NO20012490D0 (no) Anvendelse av staurosporinderivater for behandling av okul¶re neovaskul¶re sykdommer
BR0113646A (pt) Tratamento de distúrbios inflamatórios
TNSN95068A1 (fr) Oligonucleotides pour inhiber le role des isoprenyl proteine transferases
WO2003050504A3 (fr) Methodes et compositions de traitement d'une maladie cardio-vasculaire a l'aide des genes 1419, 58765 et 2201
ATE300947T1 (de) Behandlung von erkrankungen mit zystenbildung
ES2098273T3 (es) Diagnostico y tratamiento de los trastornos neuro-cognitivos asociados a una disfuncion inmunologica sistemica.
ATE376425T1 (de) Verfahren zur behandlung bestimmter augenkrankheiten
ATE344054T1 (de) Behandlung von okularen neovaskularen erkrankungen